Related Experiment Video
Updated: Feb 9, 2026

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism
Published on: August 19, 2021
Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic
1Neuropharma SA, Avenida de la Industria 52, 28760 Tres Cantos, Madrid, Spain. mmedina@neuropharma.es
Abstract:
It is just over a quarter of a century since the original identification and characterization of glycogen synthase kinase-3 (GSK-3), a major protein kinase that is involved in the regulation of glucose metabolism. GSK-3 modulates the function of a diverse series of proteins, as well as being associated with a wide variety of human disorders, including neurodegenerative diseases, stroke, bipolar disorder, diabetes and cancer. Not surprisingly, GSK-3 has attracted significant attention as a therapeutic target and as a means to understand the molecular basis of these disorders. Small-molecule GSK-3 inhibitors have now started to reach clinical development for the treatment of various disorders.
Related Concept Videos
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Piaget's Stage 3 of Cognitive Development
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
ATP Synthase: Structure

